Earnings Releases, Pricing Updates, and Stock Price Movements - Analyst Notes on Valero, Praxair, Total SA, Isis Pharmaceuticals and Cigna

Mon May 5, 2014 8:00am EDT

* Reuters is not responsible for the content in this press release.

Earnings Releases, Pricing Updates, and Stock Price Movements - Analyst Notes on Valero, Praxair, Total SA, Isis Pharmaceuticals and Cigna

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, May 5, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Valero Energy Corporation (NYSE: VLO), Praxair Inc. (NYSE: PX), Total SA (NYSE: TOT), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and Cigna Corporation (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2050-100free.

Valero Energy Corporation Analyst Notes
On April 29, 2014, before market hours, Valero Energy Corporation (Valero) reported its financial results of Q1 2014. According to Valero, operating revenues for Q1 2014 were $33.66 billion, up 0.6% YoY beating analysts' estimates of $32.95 billion. Valero reported net income attributable to stockholders of $828 million, or $1.54 per diluted share, compared to $654 million, or $1.18 per diluted share, in Q1 2013. Analysts' estimates by Thomson Reuters expected EPS of $1.38 for Q1 2014. The Company reported Q1 2014 operating income of $1.4 billion, versus $1.1 billion in Q1 2013. According to Valero, the increases in operating income in the refining and ethanol segments were partly offset by a reduction from the offshoot of the retail segment, CST Brands, Inc., on May 1, 2013. The full analyst notes on Valero are available to download free of charge at:


Praxair Inc. Analyst Notes
On April 30, 2014, Praxair, Inc. (Praxair) issued a press release announcing increase in prices for Argon with effect from May 15, 2014. According to the press release, Praxair will hike prices up to 20% for argon, and up to 15% for argon facility fees or monthly bulk product charges. The hike is applicable for bulk and packaged industrial, and specialty customers in the U.S. and Puerto Rico and will vary as permitted by individual supply contracts. The Company stated that over the past few years, the demand for Argon has outstripped capacity, requiring investments in production capacity upgrades and additional distribution resources. According to Praxair, combination of these and other investments to ensure uninterrupted supply have increased argon costs drastically. Argon is mostly used as an inert shielding gas in welding and other high-temperature industrial processes. The full analyst notes on Praxair are available to download free of charge at:


Total SA Analyst Notes
On April 30, 2014, the French integrated international Oil & Gas Company - Total SA (Total) reported financial results of Q1 2014. For Q1 2014 sales declined 4.5% YoY to $60.7 billion, while net income was $3.3 billion, as compared to $3.7 billion, in Q1 2013. Q1 2014, adjusted net operating income from business segments declined 8.12% YoY to $3.7 billion. According to Total, this decrease was mainly due to fall in the Upstream results in line with the decrease in Brent and the lower contribution of the Refining & Chemicals and Marketing & Services segment, which were impacted by a much weaker environment in Europe. The Company reported earnings of $1.46 per diluted share in Q1 2014, which matched Zacks analysts' estimates. The Company also declared Q1 2014 interim dividend of €0.61 per share payable on September 26, 2014. The full analyst notes on Total SA are available to download free of charge at:


Isis Pharmaceuticals, Inc. Analyst Notes
On April 30, 2014, stock of Isis Pharmaceuticals, Inc. (Isis Pharmaceuticals) closed at $26.61 down by 9.46%. Isis Pharmaceutical's stock opened at $29.00 and oscillated between $24.34 and $29.25 during the trading session. The trading volume for the day climbed to 10.15 million shares as compared to the previous days' trading volume of 4.92 million. During the last one month, the stock has declined considerably by 38.42%. The Company will release the financial results for Q1 2014 on May 6, 2014, before market opening and is expected to post loss per share of 23 cents, as indicated by Zacks.com. The full analyst notes on Isis Pharmaceuticals are available to download free of charge at:


Cigna Corporation Analyst Notes
On May 1, 2014, Cigna Corporation (Cigna) reported Q1 2014 financial results. For Q1 2014, Cigna reported consolidated revenues of $8.5 billion, up 3.8% YoY. According to Cigna, revenues reflect growth in premiums and fees of 3% in Global Health Care, 13% in Global Supplemental Benefits and 7% in Group Disability and Life, primarily driven by continued growth in Cigna's targeted customer. Q1 2014 net income was $528 million, or $1.92 per share, as against $57 million, or $0.20 per share in Q1 2013. Analysts polled by Thomson Reuters expected EPS of $1.54 for Q1 2014. In addition, Cigna raised its 2014 adjusted income from operations to be in the range of $1.93 billion to $2.0 billion, or $7.05 to $7.35 per share. The full analyst notes on Cigna are available to download free of charge at:


About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.